ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in…
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Collaboration with OneThree Biotech identifies novel RSV treatments
First…
IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy
Funding will support iOnctura’s clinical program for IOA-289,…
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Statistically significant improvements in lung function, symptoms…
Cutting-edge protein design project to join BioInnovation Institute’s Bio Studio program
BioInnovation Institute (BII), an international enterprise foundation…
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
Financing from new investors Trill Impact Ventures and Pureos…
Alchemab Therapeutics | The Chain Podcast
THE CHAIN PODCAST
Our Co-Founder and CSO Jane Osbourn was delighted…
Biocomposites announce a year of record sales and company growth
Winner of two Queen’s Awards for Enterprise in Innovation…
ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy
Los Angeles, USA and New York, USA, December 14, 2022 – ImaginAb…
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
Clinical trial to demonstrate technology can safely deliver GLP-1…
STORM Therapeutics announces closing of USD $30M Series B financing
Proceeds will advance STORM’s potential first-in-class…
Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards
AMSTERDAM, THE NETHERLANDS, December 13, 2022 – Synaffix B.V.…
Futura Medical provide update on a milestone year of regulatory and commercial progress for MED3000
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
CellCentric presents early clinical data at ASH
Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor…
Poolbeg Pharma plc. POLB 001 LPS human challenge clinical trial successfully completed. No serious adverse events reported. Results of full data analysis expected in Q2 2023
12 December 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
